Drug Trial Radar · NCT06225544
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 14, 2024
Primary completion
Jan 30, 2025
Study completion Mar 1, 2025
Sponsor
- Lead sponsor
- Charite University, Berlin, GermanyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alnylam Pharmaceuticals
- First posted
- Jan 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis. The study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study. At the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.
Conditions
- Haemodialysis
- Chronic Kidney Disease Requiring Chronic Dialysis
- Cardiovascular Disease
- Cardiovascular Risk Factor
- Hyperoxalemia
Interventions
LumasiranDrug
Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
0.9% Sodium Chloride (placebo)Drug
Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-dialysis Plasma Oxalate concentrationTime frame: It will be measured at baseline and month 1-6 (weeks 4, 8, 12, 16, 20 and 24).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Charite Universtiätsmedizin
Berlin, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.